# Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

> **NCT02630199** · PHASE1 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 65 (actual)

## Conditions studied

- Refractory Cancer

## Interventions

- **DRUG:** AZD6738
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02630199
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2020-12
- **Final completion:** 2021-04-19
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630199, "Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02630199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*